Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
The company said it is shifting focus from demonstrating clinical validity to proving its test can improve patient care and outcomes.
IndivuTest will offer the Sysmex Inostics OncoBEAM test in Germany, Austria, and Switzerland under an exclusive distribution agreement.
The work could have implications not only for noninvasive prenatal testing, but also for oncology for detecting epigenetic changes in circulating tumor DNA.
CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans."
With the support of the new funds, the company hopes to launch its NeoLiquid test by the end of this year after completing beta tests.
Vendors and clinicians are struggling with how to deal with the growing number of cases of secondary findings from molecular non-invasive prenatal tests.
Management provided an update on reimbursement and new products in the works for whole-genome karyotyping, carrier screening, and oncology.
Sales of Illumina's HiSeq X Ten and NextSeq 500 instruments helped drive record revenues of $512.4 million in the fourth quarter of 2014.
Recent studies demonstrate that next-generation sequencing of ctDNA or CTCs can give a representative picture of a patient's tumor.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.